Amntadin-Therapie - Ein unabhangiger Pradiktor einer verbesserten Uberlebensrate bei Morbus Parkinson

Translated title of the contribution: Amantadine treatment is an independent predictor of improved survival in Parkinson's disease

R. J. Uitti, A. H. Rajput, J. E. Ahlskog, K. P. Offord, D. R. Schroeder, M. M. Ho, M. Prasad, A. Rajput, P. Basran

Research output: Contribution to journalArticle

Abstract

Amantadine has been used for more than 20 years in the symptomatic treatment of Parkinson's disease (PD). Several recent discoveries suggest that amantadine could also have a neuroprotective effect in PD. We studied survival in all parkinsonism (including PD and other parkinsonian syndromes) patients attending a single clinic, employing standard survival curves and a Cox regression model, to identify independent predictive variables for survival (while taking into account factors potentially associated with both outcome and treatment selection). Amantadine-treated patients (n = 250) were similar to the patients not treated with amantadine (n = 586) in terms of age, gender, type of parkinsonism, Hoehn and Yahr stage and dementia status at initial neurological visit. Amantadine use was an independent predictor of improved survival (p < 0.01). Improved survival was also associated with a higher 10-year expected survival (based on age, gender, and birth year), absence of dementia, type of parkinsonism = PD, and low Hoehn and Yahr stage (I or II) at initial neurologic visit (all p < 0.01); these additional factors occurred in statistically similar proportions in the groups that were and were not treated with amantadine. The association of improved survival with amantadine use may stem from symptomatic benefit or may reflect a 'neuroprotective' effect, mediated through N-methyl-D-aspartate (NMDA) receptor antagonism, dopamine uptake blockade activity, or other mechanisms. Our preliminary findings suggest that a prospective, controlled, randomized trial of amantadine's effects on PD progression is warranted.

Original languageGerman
Pages (from-to)417-423
Number of pages7
JournalNervenheilkunde
Volume16
Issue number7
StatePublished - Sep 1997

Fingerprint

Amantadine
Parkinson Disease
Survival
Parkinsonian Disorders
Neuroprotective Agents
Therapeutics
Dementia
Secondary Parkinson Disease
N-Methyl-D-Aspartate Receptors
Proportional Hazards Models
Nervous System
Disease Progression
Dopamine
Randomized Controlled Trials
Parturition

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Uitti, R. J., Rajput, A. H., Ahlskog, J. E., Offord, K. P., Schroeder, D. R., Ho, M. M., ... Basran, P. (1997). Amntadin-Therapie - Ein unabhangiger Pradiktor einer verbesserten Uberlebensrate bei Morbus Parkinson. Nervenheilkunde, 16(7), 417-423.

Amntadin-Therapie - Ein unabhangiger Pradiktor einer verbesserten Uberlebensrate bei Morbus Parkinson. / Uitti, R. J.; Rajput, A. H.; Ahlskog, J. E.; Offord, K. P.; Schroeder, D. R.; Ho, M. M.; Prasad, M.; Rajput, A.; Basran, P.

In: Nervenheilkunde, Vol. 16, No. 7, 09.1997, p. 417-423.

Research output: Contribution to journalArticle

Uitti, RJ, Rajput, AH, Ahlskog, JE, Offord, KP, Schroeder, DR, Ho, MM, Prasad, M, Rajput, A & Basran, P 1997, 'Amntadin-Therapie - Ein unabhangiger Pradiktor einer verbesserten Uberlebensrate bei Morbus Parkinson', Nervenheilkunde, vol. 16, no. 7, pp. 417-423.
Uitti RJ, Rajput AH, Ahlskog JE, Offord KP, Schroeder DR, Ho MM et al. Amntadin-Therapie - Ein unabhangiger Pradiktor einer verbesserten Uberlebensrate bei Morbus Parkinson. Nervenheilkunde. 1997 Sep;16(7):417-423.
Uitti, R. J. ; Rajput, A. H. ; Ahlskog, J. E. ; Offord, K. P. ; Schroeder, D. R. ; Ho, M. M. ; Prasad, M. ; Rajput, A. ; Basran, P. / Amntadin-Therapie - Ein unabhangiger Pradiktor einer verbesserten Uberlebensrate bei Morbus Parkinson. In: Nervenheilkunde. 1997 ; Vol. 16, No. 7. pp. 417-423.
@article{60bd79be4c304c2e80175bb28587c233,
title = "Amntadin-Therapie - Ein unabhangiger Pradiktor einer verbesserten Uberlebensrate bei Morbus Parkinson",
abstract = "Amantadine has been used for more than 20 years in the symptomatic treatment of Parkinson's disease (PD). Several recent discoveries suggest that amantadine could also have a neuroprotective effect in PD. We studied survival in all parkinsonism (including PD and other parkinsonian syndromes) patients attending a single clinic, employing standard survival curves and a Cox regression model, to identify independent predictive variables for survival (while taking into account factors potentially associated with both outcome and treatment selection). Amantadine-treated patients (n = 250) were similar to the patients not treated with amantadine (n = 586) in terms of age, gender, type of parkinsonism, Hoehn and Yahr stage and dementia status at initial neurological visit. Amantadine use was an independent predictor of improved survival (p < 0.01). Improved survival was also associated with a higher 10-year expected survival (based on age, gender, and birth year), absence of dementia, type of parkinsonism = PD, and low Hoehn and Yahr stage (I or II) at initial neurologic visit (all p < 0.01); these additional factors occurred in statistically similar proportions in the groups that were and were not treated with amantadine. The association of improved survival with amantadine use may stem from symptomatic benefit or may reflect a 'neuroprotective' effect, mediated through N-methyl-D-aspartate (NMDA) receptor antagonism, dopamine uptake blockade activity, or other mechanisms. Our preliminary findings suggest that a prospective, controlled, randomized trial of amantadine's effects on PD progression is warranted.",
author = "Uitti, {R. J.} and Rajput, {A. H.} and Ahlskog, {J. E.} and Offord, {K. P.} and Schroeder, {D. R.} and Ho, {M. M.} and M. Prasad and A. Rajput and P. Basran",
year = "1997",
month = "9",
language = "German",
volume = "16",
pages = "417--423",
journal = "Nervenheilkunde",
issn = "0722-1541",
publisher = "Schattauer GmbH",
number = "7",

}

TY - JOUR

T1 - Amntadin-Therapie - Ein unabhangiger Pradiktor einer verbesserten Uberlebensrate bei Morbus Parkinson

AU - Uitti, R. J.

AU - Rajput, A. H.

AU - Ahlskog, J. E.

AU - Offord, K. P.

AU - Schroeder, D. R.

AU - Ho, M. M.

AU - Prasad, M.

AU - Rajput, A.

AU - Basran, P.

PY - 1997/9

Y1 - 1997/9

N2 - Amantadine has been used for more than 20 years in the symptomatic treatment of Parkinson's disease (PD). Several recent discoveries suggest that amantadine could also have a neuroprotective effect in PD. We studied survival in all parkinsonism (including PD and other parkinsonian syndromes) patients attending a single clinic, employing standard survival curves and a Cox regression model, to identify independent predictive variables for survival (while taking into account factors potentially associated with both outcome and treatment selection). Amantadine-treated patients (n = 250) were similar to the patients not treated with amantadine (n = 586) in terms of age, gender, type of parkinsonism, Hoehn and Yahr stage and dementia status at initial neurological visit. Amantadine use was an independent predictor of improved survival (p < 0.01). Improved survival was also associated with a higher 10-year expected survival (based on age, gender, and birth year), absence of dementia, type of parkinsonism = PD, and low Hoehn and Yahr stage (I or II) at initial neurologic visit (all p < 0.01); these additional factors occurred in statistically similar proportions in the groups that were and were not treated with amantadine. The association of improved survival with amantadine use may stem from symptomatic benefit or may reflect a 'neuroprotective' effect, mediated through N-methyl-D-aspartate (NMDA) receptor antagonism, dopamine uptake blockade activity, or other mechanisms. Our preliminary findings suggest that a prospective, controlled, randomized trial of amantadine's effects on PD progression is warranted.

AB - Amantadine has been used for more than 20 years in the symptomatic treatment of Parkinson's disease (PD). Several recent discoveries suggest that amantadine could also have a neuroprotective effect in PD. We studied survival in all parkinsonism (including PD and other parkinsonian syndromes) patients attending a single clinic, employing standard survival curves and a Cox regression model, to identify independent predictive variables for survival (while taking into account factors potentially associated with both outcome and treatment selection). Amantadine-treated patients (n = 250) were similar to the patients not treated with amantadine (n = 586) in terms of age, gender, type of parkinsonism, Hoehn and Yahr stage and dementia status at initial neurological visit. Amantadine use was an independent predictor of improved survival (p < 0.01). Improved survival was also associated with a higher 10-year expected survival (based on age, gender, and birth year), absence of dementia, type of parkinsonism = PD, and low Hoehn and Yahr stage (I or II) at initial neurologic visit (all p < 0.01); these additional factors occurred in statistically similar proportions in the groups that were and were not treated with amantadine. The association of improved survival with amantadine use may stem from symptomatic benefit or may reflect a 'neuroprotective' effect, mediated through N-methyl-D-aspartate (NMDA) receptor antagonism, dopamine uptake blockade activity, or other mechanisms. Our preliminary findings suggest that a prospective, controlled, randomized trial of amantadine's effects on PD progression is warranted.

UR - http://www.scopus.com/inward/record.url?scp=0030767430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030767430&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0030767430

VL - 16

SP - 417

EP - 423

JO - Nervenheilkunde

JF - Nervenheilkunde

SN - 0722-1541

IS - 7

ER -